Inojosa H, Schriefer D, Ness NH, Dillenseger A, et al. Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study. J Neurol 2025;272:153.
PMID: 39821478